BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9293796)

  • 21. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galactose-conjugated antibodies in cancer therapy: properties and principles of action.
    Ong GL; Ettenson D; Sharkey RM; Marks A; Baumal R; Goldenberg DM; Mattes MJ
    Cancer Res; 1991 Mar; 51(6):1619-26. PubMed ID: 1998953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.
    Shih LB; Thorpe SR; Griffiths GL; Diril H; Ong GL; Hansen HJ; Goldenberg DM; Mattes MJ
    J Nucl Med; 1994 May; 35(5):899-908. PubMed ID: 8176479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells.
    Mattes MJ; Griffiths GL; Diril H; Goldenberg DM; Ong GL; Shih LB
    Cancer; 1994 Feb; 73(3 Suppl):787-93. PubMed ID: 8306261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
    Zhu H; Baxter LT; Jain RK
    J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
    Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
    Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental approaches to increase radiolabeled antibody localization in tumors.
    Buchsbaum DJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5729s-5732s. PubMed ID: 7493336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunoscintigraphy and radioimmunotherapy in nude mouse models. Studies with site-specifically modified monoclonal antibodies.
    Alvarez VL; Lopes AD; Rodwell JD; McKearn TJ; Stuart FP
    Targeted Diagn Ther; 1989; 2():99-118. PubMed ID: 2519552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application.
    Werlen RC; Lankinen M; Offord RE; Schubiger PA; Smith A; Rose K
    Cancer Res; 1996 Feb; 56(4):809-15. PubMed ID: 8631018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
    Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
    Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.